gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NYSE · DNAHealthcareBiotechnology

Ginkgo Bioworks Holdings, Inc. (DNA)

$11.65+8.27%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$11.65▲ 0.52% in range
Nov 4, 2025Low $5.48 · High $14.98Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Ginkgo Bioworks Holdings closed at $11.65 on Nov 4, up 8.27%, 22.2% below its 52-week closing high. Volume of 2.7M shares was 0.96× its 20-day average (close to normal).

Split-adjusted performance: -6.1% over one month, +15.6% over six months, -8.9% over one year.

In the quarter ended Jun 30, 2026, revenue was $20.16M, down 48.5% from a year earlier, with a net margin of -231.7%.

Short interest was 8.3M shares at the Oct 15 settlement, up 13.4% from the prior report (18.4% of float, 1.9 days to cover).

Market cap$784.5M67.3M shares
Revenue · quarter$20.2M−48.5% YoY
Diluted EPS$-0.75—
P/E · TTM—P/S 7.0×
Net margin-231.7%Gross 91.5%
Dividend yieldNone
52-week range5.48 – 14.98−22.2% from high
Volume2.7M0.96× 20-day avg
Volatility · 60d128.9%Annualised
Short % of float18.4%1.9 days to cover
Net cash$302.2MCash $302.2M
Next earnings—Not scheduled
Split-adjusted performance
1W −12.5%1M −6.1%3M +37.1%6M +15.6%YTD +40.2%1Y −8.9%3Y −78.1%5Y −98.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum77
Revenue growth24
Net margin52
Value (low P/E)—
Size69

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short8.3M+13.4% vs prior
Days to cover1.9Settled Oct 15
% of float18.4%
Short vol. 10d53.8%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
DNAGinkgo Bioworks Holdings$11.65+8.27%+15.6%−48.5%−231.7%—$784.5M
SANASana Biotechnology$2.56+4.92%−29.7%———$766.4MCompare
CGEMCullinan Therapeutics$12.49−20.70%−16.7%———$803.8MCompare
ATTOAttovia Therapeutics$15.60+2.16%————$712.2MCompare
SLDBSolid Biosciences$6.52+3.82%−9.4%———$699.1MCompare
CADLCandel Therapeutics$9.05+2.61%+18.6%———$692.5MCompare
AURAAura Biosciences$6.65+6.57%−19.8%———$689.6MCompare
PRMEPrime Medicine$4.97+9.23%+45.7%+3.5%−3649.0%—$901.4MCompare
MGTXMeiraGTx Holdings$9.42−1.05%−4.8%+8608.6%50.0%11.5$904.7MCompare

News about Ginkgo Bioworks Holdings

All news →
Ginkgo Bioworks Holdings, Inc. (DNA) Suffers a Larger Drop Than the General Market: Key InsightsZacks Investment Research · 6d ago▼ NegativeGinkgo Bioworks Holdings, Inc. (DNA) Stock Falls Amid Market Uptick: What Investors Need to KnowZacks Investment Research · Oct 20, 2026▼ NegativeHere's Why Ginkgo Bioworks Holdings, Inc. (DNA) Fell More Than Broader MarketZacks Investment Research · Oct 14, 2026▼ NegativeGinkgo Bioworks Holdings, Inc. (DNA) Falls More Steeply Than Broader Market: What Investors Need to KnowZacks Investment Research · Oct 7, 2026▼ NegativeGinkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to KnowZacks Investment Research · Sep 23, 2026▼ Negative

Quick answers

What does Ginkgo Bioworks Holdings do?
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats.
What is DNA's market cap?
$784.51M, based on the Nov 4 close of $11.65.
Does Ginkgo Bioworks Holdings pay a dividend?
No regular cash dividend has been paid in the last year.
How much of DNA is sold short?
8.3M shares, 18.4% of float, as of Oct 15, 2026.
What sector is DNA in?
Healthcare, in the Biotechnology industry.

About Ginkgo Bioworks Holdings

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.

HQ: Boston, MA485 employeesListed Apr 19, 2021ginkgobioworks.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology